Previous 10 | Next 10 |
CAMBRIDGE, Mass. and NESS ZIONA, Israel, Nov. 30, 2023 (GLOBE NEWSWIRE) -- BiomX Inc. (NYSE American: PHGE) (“BiomX” or the “Company”), a clinical-stage company advancing novel natural and engineered phage therapies that target specific pathogenic bacteria, today annou...
2023-11-29 07:11:39 ET More on BiomX BiomX: BX004 Phage Cocktail Part 2, Phase 1b/2a Clinical Results In Cystic Fibrosis Expected Any Day Seeking Alpha’s Quant Rating on BiomX Historical earnings data for BiomX Financial information for BiomX F...
BX004 showed clinically meaningful improvement in pulmonary function as measured in FEV1 1 and C ystic F ibrosis Questionnaire - R evised (CFQ-R) respiratory domain in a predefined subgroup of patients wit...
2023-11-23 07:43:09 ET Summary BiomX announced positive results from Part 1 of its Phase 1b/2a study for its novel phage cocktail, BX004, treating chronic pulmonary infections caused by P. aeruginosa bacteria in Cystic Fibrosis. Part 1 study was small (N=9), double-blind, BX004 th...
2023-11-14 06:40:34 ET More on BiomX Seeking Alpha’s Quant Rating on BiomX Historical earnings data for BiomX Financial information for BiomX For further details see: BiomX GAAP EPS of -$0.13 misses by $0.03
A nalysis of Part 2 data from Phase 1b/2a trial of BX004 ongoing; Company expects to announce Part 2 data later this month BX004 received FDA Fast Track designation in August Part 1 data recently presented at the North American Cystic Fibrosis Conference (NACFC) CAMBRIDGE,...
CAMBRIDGE, Mass. and NESS ZIONA, Israel, Oct. 27, 2023 (GLOBE NEWSWIRE) -- BiomX Inc. (NYSE American: PHGE) (“BiomX” or the “Company”), a clinical-stage company advancing novel natural and engineered phage therapies that target specific pathogenic bacteria, today annou...
CAMBRIDGE, Mass. and NESS ZIONA, Israel, Oct. 18, 2023 (GLOBE NEWSWIRE) -- BiomX Inc. (NYSE American: PHGE) (“BiomX”), a clinical-stage company advancing novel natural and engineered phage therapies that target specific pathogenic bacteria, today announced the appointment of Edward ...
Company remains on track to report Part 2 results from the study in November 2023 Part 1 data of the Phase 1b/2a study accepted for oral presentation at upcoming IDWeek 2023 CAMBRIDGE, Mass. and NESS ZIONA, Israel, Oct. 04, 2023 (GLOBE NEWSWIRE) -- BiomX In...
CAMBRIDGE, Mass. and NESS ZIONA, Israel, Sept. 07, 2023 (GLOBE NEWSWIRE) -- BiomX Inc. (NYSE American: PHGE) (“BiomX” or the “Company”), a clinical-stage company advancing novel natural and engineered phage therapies that target specific pathogenic bacteria, today anno...
News, Short Squeeze, Breakout and More Instantly...
Chardan Healthcare Acquisition Corp. Company Name:
PHGE Stock Symbol:
NYSE Market:
GAITHERSBURG, Maryland and NESS ZIONA, Israel, May 15, 2024 (GLOBE NEWSWIRE) -- BiomX Inc. (NYSE:PHGE) ("BiomX" or the "Company"), a clinical-st...
GAITHERSBURG, Maryland and NESS ZIONA, Israel, May 15, 2024 (GLOBE NEWSWIRE) -- BiomX Inc. (NYSE American: PHGE) (“BiomX” or the “Company”), a clinical-stage company advancing novel natural and engineered phage therapies that target specific pathogenic bacteria, today ...
CAMBRIDGE, Mass. and NESS ZIONA, Israel, May 06, 2024 (GLOBE NEWSWIRE) -- BiomX Inc. (NYSE:PHGE) ("BiomX" or the "Company"), a clinical-stage co...